Publication Name	World Journal of Clinical Oncology
Manuscript ID	19740
Country	Australia

Received	2015-05-20 09:25
Peer-Review Started	2015-05-20 19:16
To Make the First Decision	2015-07-27 15:46
Return for Revision	2015-08-04 09:31
Revised	2015-08-25 00:00
Second Decision	2015-09-28 14:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-10-13 17:52
Articles in Press	2015-10-13 17:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-28 17:49
Publish the Manuscript Online	2015-12-09 18:37

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Combination therapies improve the anticancer activities of retinoids in neuroblastoma
Manuscript Source	Invited Manuscript
All Author List	Belamy B Cheung
Funding Agency and Grant Number
Corresponding Author	Belamy B Cheung, PhD, Molecular Carcinogenesis Program, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, PO Box 81, Randwick, Sydney NSW 2031, Australia. bcheung@ccia.unsw.edu.au
Key Words	Retinoids; Histone deacetylase inhibitors; Combination therapies; Neuroblastoma; Fenretinide
Core Tip	Neuroblastoma (NB) begins in embryonal neural crest cells, which later give rise to the sympa-thetic nervous system, and is caused in part by factors which arrest differentiation. In vitro, retinoids force susceptible cancer cells down a pathway of terminal differentiation and, have been part of the routine treatment of advanced NB for number of decades. Synergistic anti-tumour activity between histone deacetylase inhibitors and retinoids has been observed in a variety of preclinical models. This editorial note discusses some of these findings on the combination therapies for improving the anticancer activities of retinoids in NB.
Publish Date	2015-12-09 18:37
Citation	Cheung BB. Combination therapies improve the anticancer activities of retinoids in neuroblastoma. World J Clin Oncol 2015; 6(6): 212-215
URL	http://www.wjgnet.com/2218-4333/full/v6/i6/212.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i6.212

Full Article (PDF)	WJCO-6-212.pdf
Full Article (Word)	WJCO-6-212.doc
Manuscript File	19740-Review.docx
Answering Reviewers	19740-Answering reviewers.pdf
Audio Core Tip	19740-Audio core tip.wav
Conflict-of-Interest Disclosure Form	19740-Conflict-of-interest statement.pdf
Copyright License Agreement	19740-Copyright assignment.pdf
Peer-review Report	19740-Peer-review(s).pdf
Scientific Misconduct Check	19740-Scientific misconduct check.pdf
Scientific Editor Work List	19740-Scientific editor work list.pdf